Top

American Journal of Clinical Dermatology

Published in:

01-07-2021 | Doxycycline | Leading Article

Rosacea: New Concepts in Classification and Treatment

Authors: Esther J. van Zuuren, Bernd W. M. Arents, Mireille M. D. van der Linden, Sofieke Vermeulen, Zbys Fedorowicz, Jerry Tan

Published in: American Journal of Clinical Dermatology | Issue 4/2021

Abstract

Rosacea is a chronic inflammatory dermatosis mainly affecting the cheeks, nose, chin, and forehead. Rosacea is characterized by recurrent episodes of flushing or transient erythema, persistent erythema, phymatous changes, papules, pustules, and telangiectasia. The eyes may also be involved. Due to rosacea affecting the face, it has a profound negative impact on quality of life, self-esteem, and well-being. In addition to general skin care, there are several approved treatment options available for addressing these features, both topical and systemic. For some features, intense pulse light, laser, and surgery are of value. Recent advances in fundamental scientific research have underscored the roles of the innate and adaptive immune systems as well as neurovascular dysregulation underlying the spectrum of clinical features of rosacea. Endogenous and exogenous stimuli may initiate and aggravate several pathways in patients with rosacea. This review covers the new phenotype-based diagnosis and classification system reflecting pathophysiology, and new and emerging treatment options and approaches. We address new topical and systemic formulations, as well as recent evidence on treatment combinations. In addition, ongoing studies investigating novel therapeutic interventions will be summarized.

van Zuuren EJ. Rosacea. N Engl J Med. 2017;377:1754–64.CrossRefPubMed

Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea Consensus (ROSCO) 2019 panel. Br J Dermatol. 2017;176:431–8.CrossRefPubMed

Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–55.CrossRefPubMed

Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol. 2020;182:1269–76. CrossRefPubMed

van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65–79.CrossRefPubMedCentralPubMed

Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(Suppl 1):S27-35.CrossRefPubMed

Tan J, Schöfer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia—the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428–34.CrossRefPubMedCentralPubMed

Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282–9.PubMed

Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722–9.CrossRefPubMed

10.

Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther (Heidelb). 2019;9:725–34.CrossRefPubMedCentralPubMed

11.

Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017;31:163–8.CrossRefPubMed

12.

Haber R, El Gemayel M. Comorbidities in rosacea: A systematic review and update. J Am Acad Dermatol. 2018;78:786–92.CrossRefPubMed

13.

Gallo RL, Granstein RD, Kang S, et al. Rosacea comorbidities and future research: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:167–70.CrossRefPubMed

14.

Holmes AD, Spoendlin J, Chien AL, et al. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78:156–66.CrossRefPubMed

15.

Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:1885.

16.

Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69:S15-26.CrossRefPubMed

17.

Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Investig Dermatol. 2015;135(6):1548–55.CrossRefPubMed

18.

Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69:1025–32.CrossRefPubMed

19.

Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Investig Dermatol. 2011;131:688–97.CrossRefPubMed

20.

Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;15(17):1562.CrossRef

21.

Kelhälä HL, Palatsi R, Fyhrquist N, et al. IL-17/Th17 pathway is activated in acne lesions. PLoS ONE. 2014;9:e105238.CrossRefPubMedCentralPubMed

22.

Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53–62.CrossRefPubMedCentralPubMed

23.

Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584–7.CrossRefPubMed

24.

Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification. Br J Dermatol. 2017;176:197–9.CrossRefPubMed

25.

Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465–71.CrossRefPubMed

26.

Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82:1501–10.CrossRefPubMed

27.

Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641–5.PubMed

28.

Sanchez J, Somolinos AL, Almodóvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53:791–7.

29.

Gold LS, Papp K, Lynde, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% Cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909–16.

30.

Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82:336–43.CrossRefPubMed

31.

Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–52.CrossRefPubMedCentralPubMed

32.

van der Linden MMD, van Ratingen AR, van Rappar DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176:1465–74.

33.

Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010;11:79–87.CrossRefPubMed

34.

Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22:287–94.CrossRefPubMed

35.

Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014;55:111–8.CrossRefPubMed

36.

Jackson JM, Kircik LH, Lorenz J. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of rosacea. J Drugs Dermatol. 2013;12:292–8.PubMed

37.

Mrowietz U, Kedem TH, Keynan R, et al. A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea. Am J Clin Dermatol. 2018;19:427–36.CrossRefPubMed

38.

Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82:1166–73.

39.

Webster G, Draelos Z, Graber E, et al. A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea. Br J Dermatol. 2020;183:471–9.CrossRefPubMedCentralPubMed

40.

Dr Reddy’s Laboratories Limited. A controlled study to assess the efficacy, safety and tolerability of oral DFD-29 extended release capsules. ClinicalTrials.gov. Identifier NCT03340961. https://clinicaltrials.gov/ct2/show/NCT03340961. Accessed 4 Dec 2020.

41.

Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13:685–8.PubMed

42.

Sol-Gel Technologies, Ltd. A study of S5G4T-1 in the treatment of papular-pustular rosacea. ClinicalTrials.gov. Identifier NCT03564119https://clinicaltrials.gov/ct2/show/NCT03564119. Accessed 1 Nov 2020.

43.

Sol-Gel Technologies, Ltd. A study of S5G4T-1 in the treatment of papulopustular rosacea. ClinicalTrials.gov. Identifier NCT03448939. https://clinicaltrials.gov/ct2/show/NCT03448939. Accessed 1 Nov 2020.

44.

Bhatia N, Werschler W, Baldwin H, et al. Efficacy and safety of micro-encapsulated benzoyl peroxide (E-BPO) cream, 5% in papulopustular rosacea: results from two phase 3, vehicle-controlled trials. Presented at Maui Derm for Dermatologists 2020, Maui, Hawaii, January 25–29, 2020.

45.

Bhatia N, Werschler W, Baldwin H, et al. Long-term efficacy and safety of benzoyl peroxide cream, 5% prepared with micro-encapsulation in papulopustular rosacea: results from an extension of two phase 3, vehicle-controlled trials. Presented at Maui Derm for Dermatologists 2020, Maui, Hawaii, January 25–29, 2020.

46.

Sol-Gel Technologies, Ltd. A long term safey study of S5G4T-1 in the treatment of papulopustular rosacea. ClinicalTrials.gov. Identifier NCT03564145. https://www.clinicaltrials.gov/ct2/show/NCT03564145. Accessed 1 Nov 2020.

47.

Park B. FDA to review investigational rosacea treatment epsolay. MPR, September 14, 2020. https://www.empr.com/home/news/drugs-in-the-pipeline/benzoyl-peroxide-epsolay-for-rosacea-fda-review/. Accessed 12 Nov 2020.

48.

Kumar AM, Chiou AS, Shih YH, et al. An exploratory, open-label, investigator initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183:942–3.CrossRefPubMed

49.

Messoud Ashina, Danish Headache Center. Efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea (STOP Ros). ClinicalTrials.gov. Identifier NCT04419259. https://clinicaltrials.gov/ct2/show/NCT04419259. Accessed 15 Nov 2020.

50.

AOBiome LLC. A study to determine safety and efficacy of b244 in subjects with mild to moderate rosacea. ClinicalTrials.gov. Identifier NCT03590366. https://www.clinicaltrials.gov/ct2/show/NCT03590366. Accessed 15 Nov 2020.

51.

Maruho Co., Ltd. Study to evaluate the long-term safety of a once-daily omiganan topical gel. ClinicalTrials.gov. Identifier NCT02576847. https://clinicaltrials.gov/ct2/show/NCT02576847. Accessed 15 Nov 2020.

52.

Maruho Co., Ltd. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. ClinicalTrials.gov. Identifier NCT02576860. https://www.clinicaltrials.gov/ct2/show/NCT02576860. Accessed15 Nov 2020.

53.

Maruho Co., Ltd. A twelve week safety and efficacy study in rosacea. ClinicalTrials.gov. Identifier NCT01784133. https://www.clinicaltrials.gov/ct2/show/NCT01784133. Accessed 15 Nov 2020.

54.

Maruho Co., Ltd. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. ClinicalTrials.gov. Identifier NCT02547441. https://www.clinicaltrials.gov/ct2/show/NCT02547441. Accessed 15 Nov 2020.

55.

Parodi A, Paolino S, Greco A, et al. S Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6:759–64.CrossRefPubMed

56.

Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2012;68:875–6.CrossRef

57.

Alfasigma S.p.A. Safety and efficacy of rifaximin in patients with papulopustular rosacea and positive lactulose breath test. ClinicalTrials.gov. Identifier NCT03864978. https://www.clinicaltrials.gov/ct2/show/NCT03864978. Accessed 30 Nov 2020.

58.

Dermata Therapeutics. DMT210 topical gel in the treatment of acne rosacea. ClinicalTrials.gov. Identifier NCT03003104. https://www.clinicaltrials.gov/ct2/show/NCT03003104. Accessed 12 Nov 2020.

59.

Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020;79:106178.CrossRefPubMed

60.

Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multi-center, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021;84:543–5.CrossRefPubMed

61.

The Royal College of Ophthalmologists. Clinical guidelines—hydroxychloroquine and chloroquine retinopathy: recommendations on monitoring, Jan 2020. Review date December 2020. https://www.rcophth.ac.uk/wp-content/uploads/2020/02/HCR-Recommendations-on-Monitoring.pdf. Accessed 6 Dec 2020.

Title: Rosacea: New Concepts in Classification and Treatment
Authors: Esther J. van Zuuren
Bernd W. M. Arents
Mireille M. D. van der Linden
Sofieke Vermeulen
Zbys Fedorowicz
Jerry Tan
Publication date: 01-07-2021
Publisher: Springer International Publishing
Keywords: Doxycycline
Minocycline
Erythema
Rosacea
Ivermectin
Brimonidine
Published in: American Journal of Clinical Dermatology / Issue 4/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-021-00595-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rosacea: New Concepts in Classification and Treatment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Recommendations for Vaccination in Children with Atopic Dermatitis Treated with Dupilumab: A Consensus Meeting, 2020

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Viral Venereal Diseases of the Skin

Behçet Disease: An Update for Dermatologists

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies